What is perimenopause and how is it different from menopause?

Perimenopause is the transitional phase before menopause, typically beginning in the early-to-mid 40s and lasting four to eight years on average. During this time estrogen levels fluctuate irregularly, producing symptoms including sleep disruption, mood changes, memory lapses, and irregular periods. Menopause is defined as the point 12 consecutive months after the final period. Post-menopause refers to all years that follow.

How does declining estrogen affect the brain, heart, and eyes specifically?

Estrogen acts as a neuroprotective agent in the brain, and its decline is associated with the 'menopause brain fog' that many women describe as memory lapses and difficulty concentrating. For the heart, estrogen had been supporting favorable LDL cholesterol levels and vascular flexibility; its decline removes that protective effect, raising cardiovascular risk significantly. For the eyes, estrogen is involved in tear film production and retinal cell protection, and dry eye disease and macular degeneration risk both increase after menopause.

What makes Meno's three new products different from existing menopause supplements?

Most menopause supplements have been formulated around symptomatic relief, targeting hot flashes, night sweats, and sleep disruption. O Positiv's three new Meno formulations address the downstream systemic effects of estrogen withdrawal on specific organs. Brain, heart, and eye are each targeted with distinct ingredient stacks, rather than a generalist formula applied to all menopause symptoms.

O Positiv Health Launches Meno Supplements for Brain, Heart, and Eye Health

Menopause supplement formulation has been dominated for years by products targeting the most visible symptoms: hot flashes, night sweats, and disrupted sleep. O Positiv Health is building on its Meno brand with a different frame, releasing three new products specifically designed for the brain, heart, and eyes in perimenopause and menopause.

The gap the new products address

Perimenopause typically begins in the early to mid-40s, before the final menstrual period, and lasts an average of four to eight years. During this phase, estrogen levels fluctuate erratically before declining permanently. The textbook symptoms (hot flashes, mood swings, sleep disruption) are the ones that prompted most product development, but estrogen withdrawal affects multiple organ systems in ways that accumulate over a longer time frame.

Women who manage through the acute symptoms successfully often face a second set of challenges that conventional menopause products never addressed. O Positiv’s three new Meno formulations are positioned to serve that need.

Brain

Estrogen functions as a neuroprotective compound, supporting blood flow in the brain and facilitating neurotransmitter signaling. When levels drop, many women experience what is commonly called “menopause brain fog”: difficulty retrieving words, short-term memory lapses, and reduced concentration. These effects are often attributed to poor sleep, which compounds them, but the neurological basis is independent of sleep quality.

The brain-health formulation targets cognitive function, memory support, and mental clarity, areas where estrogen loss creates measurable deficits.

Heart

Before menopause, women experience lower rates of cardiovascular disease than men of the same age. Estrogen contributes to this protective effect by supporting favorable LDL cholesterol levels and maintaining vascular flexibility. As estrogen declines, this advantage disappears. Cardiovascular disease incidence in women rises sharply in the decade after menopause, eventually converging with and in some measures exceeding male rates.

The heart-health formulation is designed to support cardiovascular function through this transition, addressing a risk profile that changes significantly in the post-menopausal period.

Eyes

Dry eye disease is substantially more common in women than men, and the gap widens after menopause. Estrogen is involved in regulating tear gland secretion and maintaining the stability of the tear film that protects the eye surface. Its decline leaves the eye more vulnerable to dryness, irritation, and light sensitivity. Age-related macular degeneration (deterioration of the central part of the retina responsible for sharp vision) also shows accelerated risk after menopause.

The eye-health formulation addresses both the immediate comfort dimension (tear film and ocular surface support) and longer-term protective concerns.

What the category expansion signals

Menopause wellness entered mainstream conversation over the past three to four years, driven by an unusually open public discussion among Millennial women in their 40s, direct-to-consumer supplement brands willing to name the category directly, and regulatory changes around hormone therapy. The next phase of that conversation is moving from “what is perimenopause” to “what does my body specifically need for the next 30 years.”

O Positiv’s move is one indicator. PwC’s projection of 13% annual growth in menopause investment is another. The category is growing not just in volume but in specificity. Products that address what estrogen withdrawal does to the brain, heart, and eyes represent the direction that the market is moving, not a niche within it.

Source: SupplySide